Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Tissue Regenix adds sales specialist for US orthopaedic drive

Distin is a specialist in building sales through targeted marketing and has worked for a number of other US companies.
Tissue Regenix adds sales specialist for US orthopaedic drive
Knee cartilages are expected to be approved by end of 2016

Tissue Regenix (LON:TRX)  has strengthened the management of its US operation with the appointment of Drew Distin to its new orthopaedic subsidiary.

Distin is a specialist in building sales through targeted marketing and has worked for a number of other US companies.

His remit is to plan the launch Tissue Regenix’s new range of orthopaedic products on the US.

Clinical trials are currently ongoing in Europe for OrthoPure XM (porcine meniscus) and OrthoPure XT (porcine tendon) products, with the a target a CE mark for the XM knee cartilage by the end of 2016.

In the US, Tissue will initially focus on  human tissue applications, initially starting with the human tendon (OrthoPure HT).

Tissue Regenix is currently in partnership with tissue bank Community Tissue Services (CTS) for the manufacturing of its wound care product DermaPure.

Peter Hamer, Tissue Regenix Orthopaedic’s commercial director, said Distin brings a wealth of experience.

“This is a very exciting time for Orthopaedics at Tissue Regenix as we continue enrolment of our OrthoPure XT clinical trial and await submission for the CE mark with OrthoPure XM.

“We are on course to complete these tasks within the timeline predicted."

PhilW.jpg
Why Invest In Tissue Regenix Group PLC? Read More Here

Register here to be notified of future TRX Company articles
View full TRX profile

Tissue Regenix Group PLC Timeline

Related Articles

Pollen2.jpg
July 13 2016
Updating investors, the company said turnover will be around £48.5mln, representing a rise of 12%, or 19% once the figure is adjusted for currency movements.
Cancer
May 02 2016
As UK biotechs are beating a trail to the US craving greater understanding and higher valuation, Doerfler and his team have opted to go in the opposite direction.
Picture of blood tests
June 14 2016
The study evaluated sampling and handling factors of the blood draw and storage process of the NuQ tests

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.